Aspr Rohit Joshi
School of Medicine
College of Health
A/Prof Rohit Joshi is a Medical Oncology Consultant working with the GenesisCare group at Calvary and St Andrew's Hospital. His public Staff Specialist appointment is at the Lyell McEwin Hospital.Rohit completed his undergraduate training at the Christian Medical College in India, after which he trained in Medical Oncology at the Royal Adelaide Hospital.Rohit is a Fellow of the Royal Australasian College of Physicians (FRACP), Fellow of the American College of Physicians (FACP), Fellow of the Royal College of Physicians (FRCP) and is certified by the European Society of Medical Oncology (ESMO).Rohit is a Director at Cancer Research SA (CRSA).
| Date | Position | Institution name |
|---|---|---|
| 2023 - ongoing | Associate Professor | University of Adelaide |
| 2020 - ongoing | Director | Cancer Research SA |
| 2018 - 2022 | Director, Cancer Research | Adelaide Oncology and Haematology |
| 2014 - ongoing | Consultant, Medical Oncology | GenesisCare |
| 2013 - 2017 | Director, Cancer Research and Clinical Trials | SA Health - Lyell McEwin Hospital |
| 2013 - ongoing | Consultant | SA Health - Lyell McEwin Hospital |
| 2010 - 2023 | Clinical Lecturer | University of Adelaide |
| 2008 - 2010 | Assistant Professor | Christian Medical College |
| Language | Competency |
|---|---|
| English | Can read, write, speak, understand spoken and peer review |
| Hindi | Can read, write, speak and understand spoken |
| Panjabi; Punjabi | Can read, write, speak and understand spoken |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2020 | Royal College of Physicians | United Kingdom | FRCP |
| 2015 | American College of Physicians | USA | FACP |
| 2013 | Royal Adelaide and Lyell McEwin Hospitals | Australia | FRACP |
| 1999 - 2002 | Christian Medical College | India | MD |
| 1991 - 1996 | Christian Medical College | India | MBBS |
| Date | Title | Institution name | Country |
|---|---|---|---|
| 2012 | European Certified Medical Oncologist (ECMO) | European Society of Medical Oncology | Switzerland |
| Year | Citation |
|---|---|
| 2018 | Joshi, R., & Hong, H. W. (2018). Ascites. In Mascc Textbook of Cancer Supportive Care and Survivorship (pp. 437-443). Springer International Publishing. DOI |
| 2011 | Joshi, R. (2011). Ascites. In I. N. Olver (Ed.), MASCC TEXTBOOK OF CANCER SUPPORTIVE CARE AND SURVIVORSHIP (pp. 261-265). SPRINGER-VERLAG BERLIN. DOI |
| Year | Citation |
|---|---|
| 2026 | Joshi, R., Vinayak, V., & Shenoy, V. B. (2026). Matrix stiffness drives cellular senescence through disruption of nuclear architecture and chromatin remodeling. In BIOPHYSICAL JOURNAL Vol. 125 (pp. 382a). CA, San Francisco: CELL PRESS. |
| 2026 | Vinayak, V., Joshi, R., & Shenoy, V. B. (2026). Epigenetic remodeling stores mechanical memory and stabilizes gene regulation. In BIOPHYSICAL JOURNAL Vol. 125 (pp. 26a). CA, San Francisco: CELL PRESS. |
| 2025 | Joshi, R., Zardavas, D., Ragone, A., Chica-Duque, S., Wang, Y., Liu, Y., . . . Van Tine, B. A. (2025). A first-in-human, phase 1a/b, dose-escalation/expansion study of BG-68501, a selective CDK2 inhibitor, as monotherapy or in combination with fulvestrant for patients with HR+/HER2-breast cancer and other advanced solid tumors: First disclosure of clinical data.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 3115). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS1 |
| 2025 | Heist, R., Shum, E., Garcia, E., Itchins, M., Gao, B., Han, J. -Y., . . . Kim, H. R. (2025). MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 43 (pp. 8613). IL, Chicago: LIPPINCOTT WILLIAMS & WILKINS. DOI WoS3 |
| 2025 | Joshi, S., & Joshi, R. (2025). Surviving and Thriving: Sensing and Signaling Mechanism in Alpine Himalayan Medicinal Plant<i> Nardostachys</i><i> jata</i><i>mansi</i>. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 61 (pp. 1 page). SPRINGER. |
| 2025 | Kumari, L. K., & Joshi, R. (2025). Integrating Artificial Intelligence and Multi-omics for Precision Organogenesis, Embryogenesis and Secondary Metabolite Production in<i> Ferula</i><i> assa-foetida.</i>. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 61 (pp. 1 page). SPRINGER. |
| 2025 | Gusain, S., & Joshi, R. (2025). Molecular Dynamics Underlying Elicitor-induced Fortification to Drought Stress Reveal Crosstalk Between Calcium Ions and Nitric Oxide Signaling. In IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL Vol. 61 (pp. 1 page). SPRINGER. |
| 2025 | Nguyen, C., Chew, G., & Joshi, R. (2025). EFFECT OF LETROZOLE IN FDG PET FOR BONY METASTASIS FROM BREAST CARCINOMA. In INTERNAL MEDICINE JOURNAL Vol. 55 (pp. 25-26). WILEY. |
| 2025 | Arefin, F., Forgioine, M., Maxter, T., Tallboy, T., Lamb, A., Cahyadi, N., . . . Kwatra, V. (2025). Evaluation of the Non-Small Cell Lung Cancer Referral Pathway at Northern Adelaide Local Health Network (NALHN), a Single Hospital Experience. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 21 (pp. 1 page). WILEY. |
| 2024 | Lim, A., Zobel, J., Bills, M., Hsieh, W., Crouch, B., Joshi, R., . . . Nguyen, N. (2024). Impact of intra-tumoral injection of Phosphorus-32 microparticles on vascularity in locally advanced pancreatic carcinoma. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 39 (pp. 235). WILEY. |
| 2024 | Price, T. J., Joshi, R., Karapetis, C. S., Cooper, P., Hocking, C., Singhal, N., & Townsend, A. R. (2024). Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 42 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. |
| 2024 | Penumarty, R. D., Forgione, M., Patel, D., Hocking, C., Joshi, R., & Kwatra, V. (2024). The use of durvalumab following definitive chemo-radiotherapy in unresectable stage III non-small-cell lung cancer - An experience of the Northern Adelaide Cancer Centre. In Abstracts from the COSA's 51st Annual Scientific Meeting Bridging gaps, building progress, breaking down disparities as published in Asia-Pacific Journal of Clinical Oncology Vol. 20 (pp. 256-136-256-137). United Kingdom: Wiley. DOI |
| 2023 | Jankowski, T., Soter, S., Raumlau, R., Chilingirova, N., Cholakova, M. D., Seidl, B., . . . Obrocea, M. (2023). A phase II, multi-center, open-label, dose-optimization study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Preliminary results. In ANNALS OF ONCOLOGY Vol. 34 (pp. 1 page). SPAIN, Madrid: ELSEVIER. DOI |
| 2022 | Ly, Y. J., Hocking, C., Joshi, R., Patel, D., Hong, H., McGregor, M., . . . Kwatra, V. (2022). Real-world comparative data on addition of Atezolizumab to platinum-doublet chemotherapy in extensive stage small cell lung cancer - A single South Australian institution experience. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 163-164). WILEY. |
| 2022 | Ciuleanu, T. -E., Joshi, R., Gryaznov, S., Vitoc, V., & Obrocea, M. (2022). A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC. In ANNALS OF ONCOLOGY Vol. 33 (pp. S1094). ELECTR NETWORK: ELSEVIER. DOI WoS1 |
| 2022 | Joshi, R., Goh, J., Joubert, W., Kwarta, V., Okera, M., Bishnoi, S., . . . Gargosky, S. (2022). CLINICAL UPDATE FROM A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL SINGLE AGENT STUDY OF SUPLEXA THERAPEUTIC CELLS IN PATIENTS WITH METASTATIC SOLID TUMOURS AND HAEMATOLOGIC MALIGNANCIES. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 10 (pp. A663). BMJ PUBLISHING GROUP. DOI |
| 2022 | Hays, J., Li, T., Chen, H., Zahrah, G., Frank, R., Hamm, J., . . . O'Malley, D. (2022). SAFETY AND CLINICAL ACTIVITIES OF THE ACID PH-SENSITIVE ANTI-CTLA-4 MAB ONC-392 IN OVARIAN CANCER PATIENTS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 10 (pp. A591). BMJ PUBLISHING GROUP. DOI |
| 2020 | Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., . . . Joshi, R. (2020). Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141). In CANCER RESEARCH Vol. 80 (pp. 3 pages). TX, San Antonio: AMER ASSOC CANCER RESEARCH. DOI WoS10 |
| 2020 | Chan, M. M., Hocking, C., Joshi, R., Patel, D., Singhal, N., McGregor, M., . . . Kwatra, V. (2020). A shift towards virtual multidisciplinary tumour board meeting during COVID 19 pandemic - A South Australian Survey. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 167). WILEY. |
| 2020 | Solanki, R., & Joshi, R. (2020). Outcomes in lung cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 177-178). WILEY. |
| 2017 | Townsend, A. R., Hardingham, J., Tebbutt, N. C., Karapetis, C. S., Singhal, N., Joshi, R., . . . Price, T. J. (2017). A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. DOI WoS1 |
| 2016 | Burdett, N., Hong, H., Roberts, S., Adams, J., Hocking, C., & Joshi, R. (2016). AVOIDING THE EMERGENCY DEPARTMENT: A RAPID ASSESSMENT AND SUPPORTIVE CARE CLINIC IN A BUSY AUSTRALIAN CANCER CENTER. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 12 (pp. 150). WILEY-BLACKWELL. WoS1 |
| 2015 | Patel, D., Abdghan, N., Kerr, K. -A., Row, J., Adams, J., & Joshi, R. (2015). Clinical presentation and management pattern of venous thrombosis in patients receiving chemotherapy. In ANNALS OF ONCOLOGY Vol. 26 (pp. 116-117). Singapore, SINGAPORE: OXFORD UNIV PRESS. |
| 2007 | Joshi, R., O'Neill, S., & Keefe, D. (2007). A prospective audit of inpatient medical oncology consultation patterns in a tertiary teaching hospital in South Australia. In ANNALS OF ONCOLOGY Vol. 18 (pp. 196-197). Lugano, SWITZERLAND: OXFORD UNIV PRESS. |